Emerging Single-Target Approaches to Treating Thyroid Cancer Subtypes
There may be systemic targeted therapies available for patients with advanced thyroid cancer, yet they do not last forever and the side effects of these current therapies are limiting, according to Lori J. Wirth, MD.
However, during her keynote address at the 3rd World Congress on Thyroid Cancer in Boston, Massachusetts, she stated that the era of precision genotype targeted therapy is upon us in advanced thyroid cancer, focusing on individual targets in subtypes of thyroid cancer.
Sorafenib (Nexavar) and lenvatinib (Lenvima) are both FDA approved for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC). Lenvatinib, for example, showed a 65% objective response rate (ORR) in the SELECT trial that led to its approval and a median progression-free survival (PFS) of 18.3 months compared with 3.6 months with placebo.1 For medullary thyroid cancer (MTC), both vandetanib (Caprelsa) and cabozantinib (Cometriq) are FDA approved in the setting of progressive disease, each showing a significant improvement over placebo in these patients
Comments
Post a Comment